HUGO PRESIDENT & COUNCIL
Charles Lee, USA
Charles Lee, Ph.D. is Director and Professor of the Jackson Laboratory for Genomic Medicine in Farmington, Connecticut, USA. Dr. Lee also holds an honorary Professorship at the Chinese University of Hong Kong.
Dr. Lee received his doctoral degree from the University of Alberta, Canada in 1996 and was subsequently an NSERC research fellow at the University of Cambridge, UK. He then completed his Clinical Cytogenetic fellowship at Harvard Medical School, USA and became board certified by the American Board of Medical Genetics in 2002. Dr. Lee has authored over 130 publications and serves as an advisor for several scientific and policy committees including the 1000 Genomes Project, the International Collaboration for Clinical Genomics Consortium and the US Food and Drug Administration (FDA). He is also a standing reviewer for the Genes, Health and Development Study Section at the National Institutes of Health. Dr. Lee was previously Chair of the American Society of Human Genetics Program Committee and former Associate Editor of the American Journal of Human Genetics.
Dr. Lee is the recipient of several scientific honors including a scientific Team Award from the American Association for Cancer Research, the C. Thomas Caskey lectureship from the University of South Carolina, the Ho-Am Prize in Medicine, the George Brumley Jr. Memorial Award from Duke University, and the Vandenberge Visiting Chair from the Center for Human Genetics - Katholic University of Leuven in Belgium. In 2012, Dr. Lee received the Chen New Investigator award from HUGO.
The research in Dr. Lee’s laboratory centers on the study of structural genomic variation and its contribution to understanding human diseases.
Stylianos E. Antonarakis
Stylianos E. Antonarakis is currently Professor and Chairman of Genetic Medicine at the University of Geneva Medical School, and the founding director of iGE3 (institute of Genetics and Genomics of Geneva). He is a medical, molecular, human geneticist, physician-scientist, who studied extensively the relationship between genomic and phenotypic variation. He received his MD (1975) and DSc (1982) from the University of Athens Medical School, and after a specialization in Pediatrics in the University Hospital, Athens Greece, he moved to Baltimore, Maryland to the program of Medical Genetics at the Johns Hopkins University School of Medicine with Haig H. Kazazian and Victor McKusick (1980-1983). He joined the faculty of the Johns Hopkins University in 1983 and rose to full professor of Pediatric Genetics, Biology and Medicine in 1990. In 1992 he moved to Geneva, Switzerland to chair Genetic Medicine in the University of Geneva. His research work includes the molecular bases of monogenic disorders and complex genetic disorders including the beta-thalassemias, hemophilias, and trisomy 21. His laboratory participated in the human genome sequence and functional analysis, particularly on chromosome 21. He is an international expert on disorders of chromosome 21, cloning of genes for genetic disorders, development of diagnostic tests, genome structure and function, studies of the genome variability, and conserved non-coding sequences in human DNA. He has published extensively (more than 620 well-cited papers) in the scientific literature, and is co-editor of the current edition of the classic textbook “Genetics in Medicine”; he is listed as one of the highly cited scientists by the ISI institute (more than 40,000 citations; h-index 99). He was the President of the European Society of Human Genetics (2001-2002), member of the HUGO Council and President Elect of HUGO for 2013-2016, foreign member of the Academy of Athens (2003), member of EMBO (2006). He was the co-organizer of the European School of Genetic Medicine, and in the last 28 years taught in the Bar Harbor Genetics Course, Maine. He was awarded the Society of Pediatric Research Young Investigator Award (1984), International Jerome Lejeune Prize (2004), the European Society of Human Genetics Award (2005), and was elected to the Society of Scholars of the Johns Hopkins University (2006), and the American Academy of Physicians (2010). He was awarded the Commander of the Order of Phoenix medal from the Hellenic Democracy (2007). More than 70 talented young scientists were trained in his laboratory (graduate students and postdoctoral fellows); in addition more than 25 young physicians were trained in the Medical Genetics Clinic of his department. With Haig Kazazian he has established one of the first molecular diagnostic laboratories in USA as early as 1982. He is a member of the Swiss National Science Foundation Research Council, and the Chair of the Genetics Review Panel of the EU ERC. His research laboratory was/is supported by grants from the National Institutes of Health, the European Union (including the European Research Council), and the Swiss National Science Foundation and numerous other Foundations including the Gebert and Lejeune Foundations. His is the originator of the World Down Syndrome Day. His current interests and research projects are the functional analysis of the genome, effect of human genetic variation to phenotypic variation, the molecular pathogenesis of trisomy 21 and polygenic phenotypes, the functional characterization of the conserved fraction of the genome, diagnostics and prevention of genetic disorders, and the societal implications of genetics and genome research.
Karen B. Avraham, Israel (HGM2021 Chair of Local Organizing Committee)
Prof. Karen B. Avraham is Vice Dean at the Sackler Faculty of Medicine and Professor of Human Genetics in the Department of Human Molecular Genetics and Biochemistry at Tel Aviv University. Born in Canada and raised in the U.S., Dr. Avraham received her B.A. degree in Biology from Washington University in St. Louis, Missouri, U.S., went on to perform her Ph.D. at the Weizmann Institute of Science in Rehovot, Israel and completed her post-doctoral training at the National Cancer Institute in Frederick, MD, U.S. At Tel Aviv University, Prof. Avraham’s research has centered on the discovery of disease genes, focusing on hereditary hearing loss. Her team takes a comprehensive approach to study the molecular basis of hearing loss, using genetic, developmental, biochemical, cellular and bioinformatic tools. She leads the effort in exome sequencing for the discovery of disease genes to identify mutations that are relevant for the hearing-impaired population. Her group has demonstrated that microRNAs are essential for development and function of inner ear hair cells in vertebrates through microRNA expression, mouse mutants and target identification. Prof. Avraham’s work has led to 83 peer-reviewed manuscripts and 43 reviews and book chapters. She was awarded the Sir Bernard Katz Prize from the Alexander-von Humboldt Foundation in Germany, the Bruno Memorial Prize from the Rothschild Foundation in Israel and in 2011, the Teva Prize for Groundbreaking Research in the Field of Rare Diseases from Teva Pharmaceuticals Industries in Israel.
Piero Carninci, Japan (2020 - 2021 / HUGO US Board Member)
Born and Educated in Italy he obtained his doctoral degree at the University of Trieste in 1989. From 1990 to 1995 he developed technologies for DNA extraction and DNA sequencing at Talent, a spin-off biotech.
He moved to Japan in 1995 at RIKEN, Tsukuba Life Science center and became tenure researcher in 1997. He has been developing technologies to capture full-length cDNAs, which were used for the construction of the Fantom projects. Between 2008 and 2013, he was a Team and Unit Leader and a Deputy Project Director at the RIKEN Omics Science Center in Yokohama. He has developed technologies to analyze the transcribed part of the genome (transcriptome), such as the cap-trapper and the CAGE. These technologies have been broadly used in the RIKEN Fantom projects and allowed identifying non coding RNAs as are the major output of the mammalian genome and providing comprehensive maps of the mammalian promoters. Additionally he developed a miniaturization of CAGE, in order to approach biological problems that for which there is limited amount of starting material.
From April in 2013, he is a Director of the Division Genomics Technologies and a Deputy Director of Center for Life Science Technologies, RIKEN. He has published more than 230 papers and book chapters, edited books and is a member of editorial boards of various scientific journals.
Ada Hamosh, USA (2020 - 2021 / HUGO US Board Member)
After completing medical school at Georgetown University, and residency in Pediatrics, an MPH from the Bloomberg School of Public Health, followed by fellowship in clinical and biochemical genetics at Johns Hopkins Hospital, Ada Hamosh, MD, MPH, joined the faculty of the McKusick-Nathans Institute of Genetic Medicine (IGM)of the Johns Hopkins University in 1992. She became the Dr. Frank V. Sutland Chair of Pediatric Genetics there in 2007. Her lifelong interest is in genotype-phenotype correlations and the molecular basis of mendelian disorders, beginning with cystic fibrosis, but expanding to becoming Scientific Director of Online Mendelian Inheritance in Man (OMIM®) since 2002. She is clinical director of the IGM, and has brought a primary care model to genetics practice. In addition, over the past several years, she has developed PhenoDB, a web-based tool for the collection, storage and analysis of phenotypic information, as well as variant filtering and analysis developed for the NHGRI funded Centers for Mendelian Genomics, but with broad applicability to any clinical or research lab pursuing whole exome/genome sequencing technologies. Her dream is to integrate standardized family history, phenotyping and genomic data to enable point of care support to diagnose and manage genetic disease.
Edison Liu, USA
Dr. Edison Liu is the newly appointed president and CEO of The Jackson Laboratory. Dr. Liu joins the Laboratory from the Genome Institute of Singapore. As founding executive director, Dr. Liu built the GIS from a staff of three into a major research institute of 27 laboratory groups and a staff of 270, with faculty in functional genomics, computational biology, population genetics and genome-to systems biology. Before moving to Singapore in 2001, he was the scientific director of the National Cancer Institute's Division of Clinical Sciences in Bethesda, Md.
Born in Hong Kong in 1952, Edison Liu obtained his B.S. in chemistry and psychology, as well as his M.D., at Stanford University. He served his internship and residency at Washington University's Barnes Hospital in St. Louis, followed by an oncology fellowship at Stanford. From 1982 to 1987 he was at the University of California, San Francisco, first in a haematology fellowship at Moffitt Hospital and then as a postdoctoral fellow in the laboratory of Nobel laureate J. Michael Bishop, while also serving as an instructor in the School of Medicine. From 1987 to 1996 he was at the University of North Carolina at Chapel Hill, where he rose to director of the UNC Lineberger Comprehensive Cancer Centre's Specialized Program of Research Excellence in Breast Cancer, the director of the Laboratory of Molecular Epidemiology at UNC's School of Public Health, chief of medical genetics, and chair of the Correlative Science Committee of the national cooperative clinical trials group, CALGB. Dr. Liu also held faculty positions in the UNC departments of medicine, epidemiology, biochemistry and biophysics, and in the curriculum in genetics. Dr. Edison Liu was born in Hong Kong, China, and immigrated to the United States in 1957. He received his bachelor's degree (Phi Beta Kappa) in chemistry and psychology from Stanford University where he remained to complete his M.D. in 1978. This was followed by internship and residency in internal medicine at Washington University, St. Louis, and clinical cancer fellowships at Stanford University (Oncology), and at the University of California at San Francisco (Haematology). He then pursued post-doctoral studies as a Damon-Runyan Cancer Research Fellow at the University of California at San Francisco in the laboratory of Dr. J. Michael Bishop identifying transforming genes in human leukemic states. In 1987, he joined the faculty of Medicine at the University of North Carolina at Chapel Hill. There, he developed programs in leukaemia and breast cancer research centring on molecular epidemiology and cell signalling. In 2001, Dr. Liu assumed the position of Executive Director, Genome Institute of Singapore which is a flagship programme of the Biomedical Sciences Initiative of Singapore. At the GIS, he is building an international research institute of 300 individuals focused on integrating genomic sciences with cell and medical biology. His scientific investigations have spanned molecular epidemiology to molecular biochemistry of human oncogenes and his current scientific research investigates the dynamics of whole genome gene transcription that explains biological states in cancer.
Michael Snyder, USA (2020 - 2021 / HUGO US Board Member)
Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has launched many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs both between and within species. He has also combined different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. He is a cofounder of several biotechnology companies, including Protometrix (now part of Life Tehcnologies), Affomix (now part of Illumina), Excelix, and Personalis, and he presently serves on the board of a number of companies.